Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $140 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Novo Nordisk (NVO) and maintains a $140 price target.
February 14, 2024 | 4:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirms an Overweight rating on Novo Nordisk with a $140 price target.
The reaffirmation of an Overweight rating and a $140 price target by a reputable analyst like Louise Chen from Cantor Fitzgerald is likely to instill confidence among investors and could lead to a positive short-term price movement for NVO. The specific mention of the price target provides a clear benchmark for expectations.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100